{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:56:57Z","timestamp":1781924217886,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Novel treatments are needed to improve the poor prognosis of metastatic cancers. The ELEVATE Lung&amp;amp;UC study evaluated magrolimab plus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC), metastatic small cell lung cancer (mSCLC), and metastatic urothelial carcinoma (mUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase II, open-label, multi-arm study enrolled patients who had received 1\u20132 (mNSCLC, mSCLC) or 2\u20133 prior lines of therapy (mUC) in the locally advanced\/metastatic setting. A safety run-in (SRI) cohort (mNSCLC\/mSCLC\/mUC) followed by a phase II cohort (three groups: mNSCLC, mSCLC, mUC) were planned. Primary endpoints were incidence of treatment-emergent adverse events (TEAEs; SRI and phase II) and objective response rate (ORR; phase II).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The SRI cohort (n = 9) had no dose-limiting toxicities. In phase II (mNSCLC, 29 patients; mSCLC, 42 patients; mUC, 26 patients), ORRs were 17.2% (mNSCLC), 4.8% (mSCLC), and 3.8% (mUC). Grade \u22653 magrolimab-related TEAE rates were 48.3% (mNSCLC), 47.6% (mSCLC), and 57.7% (mUC). A fatal TEAE suspected as magrolimab related (intracranial hemorrhage) occurred in one patient with mSCLC and brain metastasis (phase II). The study was closed early, which limited the interpretation of results due to short follow-up and limited endpoint maturity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Adding magrolimab to docetaxel had manageable toxicity but no meaningful improvement in efficacy. These results provide insight into the safety and efficacy of anti-CD47\u2013containing therapies and reinforce the need for treatments that address the unmet needs of patients with previously treated metastatic solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1786385","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:34:38Z","timestamp":1776832478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors"],"prefix":"10.3389","volume":"16","author":[{"given":"Antoine","family":"Italiano","sequence":"first","affiliation":[{"name":"D\u00e9partement d\u2019oncologie m\u00e9dicale \u2013 Sarcomes, Centre R\u00e9gional de Lutte Contre le Cancer (CLCC) Institut Bergoni\u00e9","place":["Bordeaux, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Garc\u00eda Manrique","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Virgen Macarena","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande Pulido","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica, MD Anderson Cancer Center","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Kerrigan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Huntsman Cancer Institute, University of Utah School of Medicine","place":["Salt Lake City, UT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Fl\u00e9chon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre L\u00e9on B\u00e9rard Centre R\u00e9gional de Lutte Contre le Cancer","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mart\u00ednez P\u00e9rez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Virgen del Roc\u00edo","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"\u017burawski","sequence":"additional","affiliation":[{"name":"Department of Outpatient Chemotherapy, Centrum Onkologii Szpital im. prof. Franciszka \u0141ukaszczyka w Bydgoszczy","place":["Bydgoszcz, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Furqan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics","place":["Iowa City, IA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Juan-Vidal","sequence":"additional","affiliation":[{"name":"Medical Oncology Service, Hospital Universitari i Polit\u00e8cnic la Fe","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulka","family":"Vaishampayan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, University of Michigan","place":["Ann Arbor, MI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene","family":"Fares","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Virginia Piper Cancer Center, Allina Health Cancer Institute","place":["Minneapolis, MN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Astera Cancer Care","place":["East Brunswick, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Vicuna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Comprehensive Cancer Centers of Nevada","place":["Las Vegas, NV, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[{"name":"Multidisciplinary Oncology and Therapeutic Innovations Department, Centre d'Essais Pr\u00e9coces en Canc\u00e9rologie de Marseille (CEPCM), Assistance Publique-H\u00f4pitaux de Marseille (AP-HM)","place":["Marseille, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.","place":["Foster City, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Song","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.","place":["Foster City, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.","place":["Foster City, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young","family":"Kim","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.","place":["Foster City, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287218814100","article-title":"The continuing role of chemotherapy in the management of advanced urothelial cancer","volume":"10","author":"G\u00f3mez De Lia\u00f1o","year":"2018","journal-title":"Ther Adv Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00277","article-title":"Addressing the unmet need in NSCLC progression with advances in second-line therapeutics","volume":"5","author":"Wang","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/lctt.s6499","article-title":"Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis","volume":"1","author":"Gubens","year":"2010","journal-title":"Lung Cancer (Auckl)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000014758","article-title":"Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed\/refractory small cell lung cancer: retrospective single-institution observational study","volume":"98","author":"Sugiyama","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215229","article-title":"CD47: the next frontier in immune checkpoint blockade for non-small cell lung cancer","volume":"15","author":"Lau","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/jci81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0906549106","article-title":"Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-1-s1-p91","article-title":"Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death","volume":"133","author":"Hodge","year":"2013","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01130-y","article-title":"A phase 1b\/2 study of the anti-CD47 antibody magrolimab with cetuximab in patients with colorectal cancer and other solid tumors","volume":"20","author":"Eng","year":"2025","journal-title":"Target Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013338","article-title":"Magrolimab plus rituximab with or without chemotherapy in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"8","author":"Maakaron","year":"2024","journal-title":"Blood Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70051","article-title":"Phase 2 multi-arm study of magrolimab combinations in patients with acute myeloid leukaemia","volume":"6","author":"Mannis","year":"2025","journal-title":"EJHaem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145903","article-title":"Final results of a phase 2 multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma","volume":"6","author":"Paul","year":"2025","journal-title":"EJHaem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B23","unstructured":"TAXOTERE prescribing information 2021\n          \n          \n          \n          2021"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"A1308","DOI":"10.1136\/jitc-2024-sitc2024.1179","article-title":"1179 Understanding the impact of magrolimab on red blood cell dynamics in humanized CD47-SIRP\u03b1 mouse model","volume":"12","author":"Yang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013283","article-title":"Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance","volume":"13","author":"Nan","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2139\/ssrn.4441797","article-title":"The antitumor activities of anti-CD47 antibodies require Fc-Fc\u03b3R interactions","volume":"41","author":"Osorio","year":"2023","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100747","article-title":"Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy","volume":"31","author":"Yang","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/jitc-2022-sitc2022.0522","article-title":"Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer","volume":"42","author":"Memon","year":"2024","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-sitc2024.0184","article-title":"Biomarker analysis of magrolimab plus docetaxel in patients with 2L+ mNSCLC from ELEVATE-Lung and UC, a phase 2 multicohort study","volume":"12","author":"van Buuren","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1786385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:34:46Z","timestamp":1776832486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1786385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1786385"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1786385","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1786385"}}